1
• Colonoscopy is among the most effective means of colorectal cancer prevention through the early detection of polyps 2 • Colon cleansing quality plays a key role in determining the diagnostic accuracy of colonoscopy 3 • There are now many competing bowel cleansing agents on the market for use in colonoscopy preparation and studies have shown significant differences in preparation quality among them 4 • In the current cost-conscious environment, a cost analysis comparing the use of Split-Dose Reduced-Volume Oral Sulfate Solution (OSS) with Polyethylene Glycol with Electrolytes Solution (PEG-ELS) provides critical insight as payers balance the trade-off between the clinical efficacy of a cleansing agent and the total cost of colonoscopy procedures
OBJECTIVE
• The study aimed to (1) develop a cost model for colonoscopy preparation among patients referred OSS (SUPREP   ®   ) and PEG-ELS (GoLYTELY ® ), (2) examine cost-savings associated with OSS versus PEG-ELS, and (3) assess the robustness of the cost model
METHODS
• An Excel-based model was developed to simulate the costs for a cohort of patients who are referred for a colonoscopy using OSS (SUPREP) or PEG-ELS (GoLYTELY) • The following assumptions were made for each cohort:
1. Patients with a family history of colorectal cancer (high risk) are referred for screening at age 40. Patients with no family history (average risk) are referred at age 50. Patients are not referred for screenings after the age of 75 2. Patients only use the cleansing agent corresponding to their cohort assignment 3. Patients who successfully completed a colonoscopy are assigned a preparation cleansing score (i.e., excellent, good, fair, or poor), with the probability of receiving each grade differing based on the cleansing agent 4. Patients are referred for colonoscopies in accordance with the recommended surveillance intervals 5. At each surveillance time interval, patients are assigned a probability of completing the colonoscopy or missing the screening (did not start preparation and did not complete the colonoscopy) 6. Costs included the cost of the cleansing agent and the colonoscopy procedure 7. Costs related to the treatment of adverse events during the preparation or procedure were the same across the agents investigated 8. When patients missed colonoscopy screenings, no cost was incurred by the payer. Such patients were either referred for another colonoscopy a year later or lost to follow-up 9. The costs for each cohort were calculated until patients reached age 75 
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Data sources
• The input parameters for the base-case model came from the following data sources:
• Results of clinical trial BLI800-440 evaluating the safety, tolerability, and efficacy of three bowel cleansing treatments (split-dose SUPREP, same day-only SUPREP, and GoLYTELY) conducted by Braintree Laboratories, Inc 5, 6 • Costs of completed and aborted colonoscopy procedures as well as the cost of SUPREP and GoLYTELY obtained from OptumHealth Reporting & Insights employer claims data 7 • Published literature estimates for the annual rate of death, annual colonoscopy completion rate, proportion of patients at high risk (i.e., family history of colonoscopy) 8, 9, 10, 11 • The ratio of 40 year-old to 50 year-old individuals from the 2010 U.S. Census 
LIMITATIONS
The following limitations apply to the cost-analysis model:
• The cycle interval is rounded to the nearest year which limits the precision of the cost differences between SUPREP and GoLYTELY • The delay interval for missed screening and aborted colonoscopy procedure is set at 1 year
CONCLUSION
• From a payer's perspective, the cost model showed that the use of SUPREP as the cleansing agent resulted in potential cost-savings compared with GoLYTELY • The cost model was robust and cost-savings under SUPREP remained under various sensitivity analyses • Higher cleansing scores and longer recommended surveillance intervals associated with SUPREP use resulted in fewer surveillance colonoscopies over the time horizon • Patients using SUPREP incurred lower colonoscopy costs than GoLYTELY patients, which offset the increased cost of the cleansing agent
